eLife:脂质可调节淋巴细胞能动性

2016-04-12 生物谷 生物谷

淋巴组织内淋巴细胞能动性的机理目前仍然未知。由日本大阪大学和图尔库大学领导的一个研究小组首次发现,一种叫做溶血磷酸酯的脂质(LPA) 在调节淋巴结内淋巴细胞能动性上起着至关重要的作用。针对LPA及其受体可能提供新的方法来控制免疫反应。 淋巴细胞是身体的“巡逻警察”。它们的作用就是寻找入侵的病原体和异常细胞(在我们的身体内任何时候都可能出现) ,在全身的血管和淋巴管中不断“巡逻”。在寻找入侵物

淋巴组织内淋巴细胞能动性的机理目前仍然未知。由日本大阪大学和图尔库大学领导的一个研究小组首次发现,一种叫做溶血磷酸酯的脂质(LPA) 在调节淋巴结内淋巴细胞能动性上起着至关重要的作用。针对LPA及其受体可能提供新的方法来控制免疫反应。

淋巴细胞是身体的“巡逻警察”。它们的作用就是寻找入侵的病原体和异常细胞(在我们的身体内任何时候都可能出现) ,在全身的血管和淋巴管中不断“巡逻”。在寻找入侵物的途中,它们总是进入淋巴结去寻找这样的入侵者,因为淋巴结是一个来自外周组织异质抗原存在的区域。一旦淋巴细胞在淋巴结内找到这样的入侵者,它们就会与其它免疫细胞一起杀死入侵物。因此, 淋巴结不仅是免疫细胞的“守卫军”,也是免疫细胞和入侵物之间斗争的地方。所以,淋巴细胞会在淋巴结内快速的移动以便有效地找到入侵物。但他们目前还不清楚愿因。

研究人员(大阪大学医学研究生院免疫调节实验室Eiji Umemoto副教授;学术研究所计划专任教授Masayuki Miyasaka ;芬兰图尔库大学MediCity研究实验室博士后研究员Masayuki Miyasaka)首次发现,一种叫做溶血磷脂酸(LPA) 的物质对调节淋巴结内淋巴细胞的能动性起着至关重要的作用。LPA是由一个特定类型的基质细胞产生的,它形成一种淋巴细胞的支架用以在各个节点间穿行过去。LPA通过特定的受体(LPA2)反过来作用于淋巴细胞,使它们能够在淋巴结狭窄的空间中有效地穿过,淋巴结上通常挤满了免疫细胞和基质细胞。

这项工作预计将引来新的方法来控制免疫反应。LPA的前体细胞大量存在于卷心菜和大豆作物中,LPA也存在于一些草药中,这个发现从健康饮食和人类健康的角度来说很有意义。

原始出处:

Takeda A, Kobayashi D, Aoi K, Sasaki N, Sugiura Y, Igarashi H, Tohya K, Inoue A, Hata E, Akahoshi N, Hayasaka H, Kikuta J, Scandella E, Ludewig B, Ishii S, Aoki J, Suematsu M, Ishii M, Takeda K, Jalkanen S, Miyasaka M, Umemoto E. Fibroblastic reticular cell-derived lysophosphatidic acid regulates confined intranodal T-cell motility. Elife. 2016 Feb 2;5. pii: e10561. doi: 10.7554/eLife.10561.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972958, encodeId=1d6119e2958de, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 21 19:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068458, encodeId=dd6520684581b, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Jun 03 11:03:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77979, encodeId=d9a2e79793b, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77980, encodeId=6b46e798064, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302021, encodeId=c5c5130202126, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Apr 14 05:03:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-06-21 膀胱癌
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972958, encodeId=1d6119e2958de, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 21 19:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068458, encodeId=dd6520684581b, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Jun 03 11:03:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77979, encodeId=d9a2e79793b, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77980, encodeId=6b46e798064, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302021, encodeId=c5c5130202126, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Apr 14 05:03:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-06-03 clmlylxy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972958, encodeId=1d6119e2958de, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 21 19:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068458, encodeId=dd6520684581b, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Jun 03 11:03:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77979, encodeId=d9a2e79793b, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77980, encodeId=6b46e798064, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302021, encodeId=c5c5130202126, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Apr 14 05:03:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1972958, encodeId=1d6119e2958de, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 21 19:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068458, encodeId=dd6520684581b, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Jun 03 11:03:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77979, encodeId=d9a2e79793b, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77980, encodeId=6b46e798064, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302021, encodeId=c5c5130202126, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Apr 14 05:03:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1972958, encodeId=1d6119e2958de, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 21 19:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068458, encodeId=dd6520684581b, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Jun 03 11:03:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77979, encodeId=d9a2e79793b, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77980, encodeId=6b46e798064, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:11:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302021, encodeId=c5c5130202126, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Apr 14 05:03:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]

相关资讯

美国国家脂质协会发布临床血脂学年度概要2015

2014年10月14日,美国国家脂质协会(NLA)发布了《临床血脂学年度概要2015》,全文在线发表于 Journal ofClinical Lipidology 。《临床血脂学年度概要2015》是一份血脂管理纲领性文件。 一、概要简介 《临床血脂学年度概要2015》是一份以血脂异常患者为中心、包含患者评估管理和护理原则等的重要性概述性文件(以下简称“概要”)。该概要计划每年均根据

JAMA:增加脂质相关性标记物与心血管疾病预测的略微改善有关

芝加哥–据6月20日刊《美国医学会杂志》JAMA上的一项研究披露,在那些没有已知心血管疾病(CVD)的人中,在含有总胆固醇和高密度脂蛋白胆固醇(HDL-C)的风险评分中加入某些载脂蛋白和脂蛋白与CVD预测的略微改善有关。 英国剑桥大学的Emanuele Di Angelantonio,M.D.及其在“新出现风险因素协作”写作组的同事开展了一项研究,旨在确定在总胆固醇和HDL-C中加入有关载脂蛋白

JACC:早期与远期脂质水平与冠脉钙化增加更相关

  美国学者的一项研究表明,与即时性脂质水平相比,早期和远期脂质水平与冠脉钙化(CAC)增加具有更强的相关性;脂质遗传学危险评分(GRS)与脂质水平相关,但无法预测CAC增加。论文于2012年10月25日在线发表于《美国心脏病学会杂志》(J Am Coll Cardiol)。   1156例弗雷明汉心脏研究(FHS)后代人群参与者接受了Exam 1(197

JCEM: 缬沙坦改善脂肪组织脂质缓冲能力

VAL和安慰剂治疗26周前后,全身和骨骼肌代谢的比较 在糖代谢异常(IGM)的人群,阻断肾素—血管紧张素系统可以降低2型糖尿病的发病率。然而,其潜在的机制有待确定。为了探讨在IGM受试者,血管紧张素Ⅱ1型受体阻断剂缬沙坦(VAL)对骨骼肌脂肪酸(FA)处理的影响,来自荷兰马斯特里赫特大学医学中心Gijs H Goossens教授及其团队进行了一项研究,该研究发现缬沙坦可以改善脂肪组织的脂质缓冲能